Valuation: PolyPid Ltd.

Market Cap 100M 87.72M 80.91M 74.72M 142M 9.56B 144M 967M 380M 4.71B 377M 368M 16.2B P/E 2026 *
-3.66x
P/E 2027 * -4.17x
Enterprise Value 100M 87.72M 80.91M 74.72M 142M 9.56B 144M 967M 380M 4.71B 377M 368M 16.2B EV / Sales 2026 *
-
EV / Sales 2027 * 7.33x
Free-Float
78.77%
Yield 2026 *
-
Yield 2027 * -
1 day-3.51%
1 week+4.18%
Current month+2.95%
1 month+15.96%
3 months+21.35%
6 months+12.72%
Current year+20.51%
1 week 5.02
Extreme 5.02
5.62
1 month 4.5
Extreme 4.5001
5.62
Current year 4.01
Extreme 4.01
5.62
1 year 3.06
Extreme 3.06
5.62
3 years 2.3
Extreme 2.3
12
5 years 2.3
Extreme 2.3
289.2
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 01/07/2022
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 18/08/2025
Director TitleAgeSince
Director/Board Member 84 01/04/2008
Director/Board Member 52 08/08/2022
Director/Board Member 74 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
03-18Other

Director

22,660 0.1187%
03-18Other

Chief Executive Officer

576,320 3.0200%
03-18Other

Chief Financial Officer

190,513 0.9983%
Change 5-day change 1-year change 3-year change Capi.($)
-3.51%+4.18%+50.72%-53.14% 100M
-2.33%-2.09%+50.33%+162.29% 1,060B
-0.82%-2.30%+62.97%+61.11% 619B
-0.73%-4.98%+27.22%+84.46% 438B
+0.33%-1.17%+27.98%+26.90% 333B
-0.02%-2.85%+25.27%+44.88% 282B
-3.89%-11.22%+20.78%+26.07% 267B
+0.66%-1.42%-29.26%-39.30% 218B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 161B
Average -1.16%-2.50%+27.03%+44.65% 357.4B
Weighted average by Cap. -0.56%-2.96%+35.28%+81.27%

Financials

2026 *2027 *
Net sales - 13.68M 11.96M 11.03M 10.19M 19.34M 1.3B 19.66M 132M 51.77M 643M 51.35M 50.23M 2.21B
Net income -33.91M -29.66M -27.36M -25.27M -47.95M -3.23B -48.76M -327M -128M -1.59B -127M -125M -5.48B -32.76M -28.66M -26.43M -24.41M -46.32M -3.12B -47.1M -316M -124M -1.54B -123M -120M -5.29B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
10/07/26 $5.230 -3.51% 256,613
09/07/26 $5.420 +4.03% 320,147
08/07/26 $5.210 -2.25% 270,008
07/07/26 $5.330 -4.48% 189,764
06/07/26 $5.580 +11.16% 504,200
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.230USD
Average target price
12.25USD
Spread / Average Target
+134.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock